The management of a large international pharma generic drugs company is are considering an acquisition of a small/mid-sized company. Currently, the management is looking to enhance its generic drugs production or distribution volume, that is why acquisition is an option. The buyer is looking at targets in all EU and non-EU countries.
The buyer is a well-established company based in the DACH region, which specializes in the development, manufacture, and sale of generic niche products in multiple fields, including
The company is large, reaching more than 500M EUR in revenue, and wants to grow externally by M&A. The company has its own laboratory and supplier a large number of hospitals, wholesalers, and pharmacies, domestic and abroad. The company is flexible and constantly invests in the development of new products to meet new market requirements.
The company has already made multiple acquisitions in Europe and Asia, in the pharmaceutical industry. Now they are looking for another acquisition, in a 1-year horizon.
Contact us to get details about this generic pharma distributor or manufacturer in Europe buyer
The company is looking for a manufacturing or distribution entity to buy, engaged preferably in generic medicine manufacturing, or front-end distribution (dossiers).
The target should have a stable or growing revenue of 5 to 25M EUR and should have a significant portion of a local pharmaceutical market share. The EBITDA of the target should be more than 15%, preferably around 20%. If target not in debt, it would be of high added value.
The location is not a decisive factor, the target can be from any European country. The target should have all the necessary accreditations. The target plant should ideally be flexible and growing in production volume.
The buyer does not focus on specific drugs/pharmaceuticals/dossiers, rather the management is exploring M&A opportunities present in Europe. Therefore, the management would b happy to consider more opportunities, partly or fully meeting the criteria mentioned above. The range of valuation, which is the buyer willing to spend for acquisition, is between 5 to 40 million EUR.
Feel free to contact us for more information regarding this generic drugs company wanted in Europe, or if you know possible interested or suitable parties. For more buyers of pharmaceutical companies please visit the section pharmaceutical companies wanted. For pharmaceutical companies for sale visit the section pharmaceutical companies for sale.
Note: CFIE only works with formal companies. We do get a lot of requests and it is difficult to follow up on all inquiries from visitors to our website. For each company, we assess the likelihood of a future transaction. We only get back to you if we see a realistic opportunity to do a future acquisition or business sale. In order to increase your chances of receiving a reply as an individual, please explain as much as possible about your personal background, strategy and fit with the target. There is also a possibility that your details will be kept on file and we will get back to you once there is an opportunity to do a transaction. CFIE can’t guarantee you will receive an answer to your request.